Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J R, Tonra"'
Autor:
J. R. Tonra, K. Garcia, V. Wong, C. Jackson, M. Ono, Stanley J. Wiegand, George D. Yancopoulos, Xiaochun Liu
Publikováno v:
Diabetes. 48:588-594
Systemic administration of brain-derived neurotrophic factor (BDNF) decreases nonfasted blood glucose in obese, non-insulin-dependent diabetic C57BLKS-Lepr(db)/lepr(db) (db/db) mice, with a concomitant decrease in body weight. By measuring percent Hb
Publikováno v:
The Journal of comparative neurology. 430(1)
Experimental autoimmune encephalomyelitis (EAE) is an animal model for human multiple sclerosis (MS). Similar to MS patients, EAE animals can exhibit chronic or relapsing, remitting paralysis; leukocyte infiltration of the central nervous system (CNS
Autor:
J R, Tonra
Publikováno v:
Microscopy research and technique. 45(4-5)
After the discovery of nerve growth factor, a classic model of neurotrophin action was developed. In this model, nerve endings compete for limited quantities of neurotrophic factors produced in neuronal target tissues. Neurotrophins are bound with hi
Autor:
K D, Cliffer, J R, Tonra, S R, Carson, H E, Radley, C, Cavnor, R M, Lindsay, S C, Bodine, P S, DiStefano
Publikováno v:
Musclenerve. 21(11)
Sensory and motor conduction velocities calculated from latencies of H reflexes and M waves in rat hind limbs have been used to assess experimental peripheral neuropathy. Amplitudes and latencies vary with recording location, and are seldom assessed
Autor:
J R, Tonra, L M, Mendell
Publikováno v:
The Journal of comparative neurology. 392(4)
Experiments were undertaken to examine anatomical correlates of physiological effects of rabbit sera raised against nerve growth factor (anti-NGF) on nociceptive afferents. This antiserum has been shown to deplete the population of A-delta high thres
Autor:
J. Haurum, W. Walton, Q. Zhou, Dipa Patel, R. Manteiga, Xiaoqiang Kang, R. Srikakulum, J. R. Tonra, B. Saxena
Publikováno v:
Journal of Clinical Oncology. 29:e21075-e21075
e21075 Background: Necitumumab, cetuximab and panitumumab are monoclonal antibodies specific for human epidermal growth factor receptor (EGFR). They act as functional antagonists by blocking ligand...
Publikováno v:
Journal of Clinical Oncology. 29:e13022-e13022
e13022 Background: Targeting the epidermal growth factor receptor (EGFR) with monoclonal antibodies has proven to be an effective therapy for the treatment of cancer. In addition to blocking activation, antibodies directed to the ligand-binding domai